Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8


DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.

J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.


HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.

van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.

PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.


Precancerous Lesions of the Breast.

Lebeau A.

Breast Care (Basel). 2010 Aug;5(4):204-206. Epub 2010 Aug 3. No abstract available.


Quantification of virtual slides: Approaches to analysis of content-based image information.

Kayser K.

J Pathol Inform. 2011 Jan 7;2:2. doi: 10.4103/2153-3539.74945.


Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.

Heerma van Voss MR, van der Groep P, Bart J, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Feb;34(1):3-10. doi: 10.1007/s13402-010-0007-3. Epub 2011 Feb 19.


Pathology of hereditary breast cancer.

van der Groep P, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Apr;34(2):71-88. doi: 10.1007/s13402-011-0010-3. Epub 2011 Feb 19. Review.


Targeting the Akt/mTOR pathway in Brca1-deficient cancers.

Xiang T, Jia Y, Sherris D, Li S, Wang H, Lu D, Yang Q.

Oncogene. 2011 May 26;30(21):2443-50. doi: 10.1038/onc.2010.603. Epub 2011 Jan 17.

Supplemental Content

Support Center